Search
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA. … [L51134] PTH(1-34) contains the N-terminal part of the endogenous PTH molecule.
Synonyms: Human parathyroid hormone (PTH) synthetic peptide fragment (1-34), conjugated at the N-terminal amino group via a cleavable linker to O-methylpolyethylene glycol (2 x 20 kDa mPEG); 2-methylalanyl-(1-34, Poly(oxy-1,2-ethanediyl), α-hydro-ω-methoxy-, ether with N-[[[2-[[6-[[1-[3-[[3-(2,3-dihydroxypropoxy)propyl]amino]-3-oxopropyl]-2,5-dioxo-3-pyrrolidinyl]thio]hexyl]amino]ethyl]amino]carbonyl]-2-methylalanyl-L-seryl-L-valyl-L-seryl-L-α-glutamyl-L-isoleEsmolol
go.drugbank.com/drugs/DB00187ApprovedInvestigationalWithdrawnIt works by blocking beta-adrenergic receptors in the heart, which leads to decreased force and rate of heart contractions. … It has a rapid onset but short duration of action without causing significant intrinsic sympathomimetic or membrane stabilizing activities at recommended therapeutic doses.
Sutimlimab
go.drugbank.com/drugs/DB14996ApprovedInvestigational[A245144] Hemolysis in patients with CAD is driven by complement activation, which initiates a cascade that ultimately leads to both intra- and extravascular hemolysis. … [L40114,A245144] Sutimlimab was also approved by the European Commission in November 2022.[L44116]
Iodide I-123
go.drugbank.com/drugs/DB09420ApprovedInvestigationalAfter incorporation, a gamma camera is used to detect the decay by electron capture to tellurium-123. … Following oral administration, I-123 is absorbed through the gastrointestinal tract and is taken up by the thyroid gland.
Filgotinib
go.drugbank.com/drugs/DB14845ApprovedInvestigational[A189165] Filgotinib is currently reserved for patients who cannot tolerate DMARDs, or who have been unable to achieve remission in response to one or more DMARDs.[L16616] … [A189165] Non-selective JAK inhibitors like [tofacitinib] target JAK1 and JAK3 subtypes with minimal activity at JAK2. In contrast, the newly approved filgotinib is a highly selective JAK1 inhibitor.
Ramipril
go.drugbank.com/drugs/DB00178ApprovedInvestigationalRamipril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is metabolized to ramiprilat in the liver and, to a lesser extent, kidneys. … Ramiprilat is a potent, competitive inhibitor of ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII).
Mixtures: RAMIPRIL COMP HEU 5/25MG NCategories: Agents Acting on the Renin-Angiotensin SystemHydroxyethyl Starch
go.drugbank.com/drugs/DB09106ApprovedInvestigationalHydroxyethyl starches (HES) are synthetic colloids commonly used for fluid resuscitation to replace intravascular volume. … HES is a general term and can be sub-classified according to average molecular weight, molar substitution, concentration, C2/C6 ratio and Maximum Daily Dose.
Autologous cultured chondrocytes
go.drugbank.com/drugs/DB10997ApprovedInvestigationalThe surgical implantation shows a tolerable safety profile and efficacy up to 4 years, but it is not indicated for patients with osteoarthritis. … Autologous cultured chrondrocytes are used as autologous cell therapy to repair articular cartilage injuries in the knee (femoral condyle) due to acute or repetitive trauma.
Vigabatrin
go.drugbank.com/drugs/DB01080ApprovedInvestigational[A202124] Its use is now generally reserved for patients who have failed alternative therapies, and its US approval by the FDA in 2009 mandated the creation of a drug registry to monitor patients for visual
Flortaucipir F-18
go.drugbank.com/drugs/DB14914ApprovedInvestigationalIt was approved by the FDA on May 28, 2020, for sale by Avid Radiopharmaceuticals under the name TAUVID™ and is the first FDA-approved molecule for imaging aggregated tau protein in the brain.[L14114] … , as well as to regions containing high levels of melanin, neuromelanin, and iron.